The American Society of Peritoneal Surface Malignancies Multi-Institution evaluation of 1,051 advanced ovarian cancer patients undergoing cytoreductive surgery and HIPEC: An introduction of the peritoneal surface disease severity score-Reference-Cited by-同舟云学术

The American Society of Peritoneal Surface Malignancies Multi-Institution evaluation of 1,051 advanced ovarian cancer patients undergoing cytoreductive surgery and HIPEC: An introduction of the peritoneal surface disease severity score

Published:2016-10-28 Issue:7 Volume:114 Page:779-784
ISSN:0022-4790
Container-title:Journal of Surgical Oncology
language:en
Short-container-title:J. Surg. Oncol.

Author:

Sleightholm Richard¹,Foster Jason M.¹,Smith Lynette¹,Ceelen Wim²,Deraco Marcello³,Yildirim Yusuf⁴,Levine Edward⁵,Muñoz-Casares Cristobal⁶,Glehen Olivier⁷,Patel Asish¹,Esquivel Jesus⁸

Affiliation:

1. Department of Surgery; University of Nebraska Medical Center; Omaha Nebraska

2. Department of Gastrointestinal Surgery; Ghent University Hospital Belgium; Gent Belgium

3. National Cancer Institute of Milan; Milan Italy

4. Department of Gynecologic Oncology; Aegean Obstetrics and Gynecology Education and Research Hospital; Izmir Turkey

5. Department of Surgery; Wake Forest University Baptist Medical Center; Winston Salem North Carolina

6. Unit of Oncological and Pancreatic Surgery, Department of General and Digestive Surgery; University Hospital Reina Sofia; Cordoba Spain

7. Service de Chirurgie Générale et Oncologique; Centre Hospitalier Lyon-Sud; Pierre-Bénite France

8. Department of Surgical Oncology; St. Agnes Hospital; Baltimore Maryland

Publisher

Wiley

Subject

Oncology,General Medicine,Surgery

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/jso.24406/fullpdf

Reference36 articles.

1. Ferlay JSI Ervik M Dikshit R http://globocan.iarc.fr

2. Patterns of recurrence in advanced epithelial ovarian, fallopian tube and peritoneal cancers treated with intraperitoneal chemotherapy;Esselen;Gynecol Oncol,2012

3. Clinical outcome of tertiary surgical cytoreduction in patients with recurrent epithelial ovarian cancer;Fotopoulou;Ann Surg Oncol,2011

4. Optimal primary surgical treatment for advanced epithelial ovarian cancer;Elattar;Cochrane Database Syst Rev,2011

5. Prognostic factors for stage III epithelial ovarian cancer: A Gynecologic Oncology Group Study;Winter;J Clin Oncol,2007

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Paclitaxel as HIPEC-Drug after Surgical Cytoreduction for Ovarian Peritoneal Metastases: A Randomized Phase III Clinical Trial (HIPECOVA);Current Oncology;2024-01-24

2. The contemporary management of peritoneal metastasis: A journey from the cold past of treatment futility to a warm present and a bright future;CA: A Cancer Journal for Clinicians;2022-08-15

3. How do we perform hyperthermic intraperitoneal chemotherapy in ovarian cancer? —a narrative review;Gland Surgery;2021-03

4. Guidelines for Perioperative Care in Cytoreductive Surgery (CRS) with or without hyperthermic IntraPEritoneal chemotherapy (HIPEC): Enhanced recovery after surgery (ERAS®) Society Recommendations — Part I: Preoperative and intraoperative management;European Journal of Surgical Oncology;2020-12

5. Prognostic factors associated with cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in recurrent ovarian cancer;International Journal of Gynecology & Obstetrics;2020-10-28